Flutamide as primary treatment for metastatic prostatic cancer.
Ten men with newly diagnosed generalised cancer of the prostate were treated with Flutamide (SCH 13521). After 18 months of treatment, one patient had stable disease and was symptom-free. Seven patients left the study because of progression of cancer and two because of the side effects of Flutamide. None of the patients with progression showed an objective response to second-line oestrogen therapy.